Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in Cervico-facial Lymphatic Malformations
NCT03243019Phase 2Recruiting
- Sponsor
- CHU de Lille
- Start
- Jun 2018
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in Lymphatic Malformation (LM), sponsored by CHU de Lille. Primary endpoint: Response rate to rapamycin at 3 months. Started Jun 2018; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Lymphatic Malformation (LM)
Beyond the preview
Go deeper on NCT03243019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243019.